GlassScriptPhysician profile
Preeti Thabolingam
NPI 1770604928
$1,202.61
in general payments reported to CMS, 2019-2025
14 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $42.07 · 2021: $71.81 · 2022: $207 · 2023: $276 · 2024: $299 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $171.21 | 2023-2024 | Azstarys |
| Tris Pharma INC | $165.60 | 2019-2025 | Dyanavel Xr |
| Alk-Abello, INC | $158.78 | 2023-2025 | Grastek, Odactra, Ragwitek |
| Merck Sharp & Dohme LLC | $145.01 | 2019-2024 | Vaxelis, M-M-R II, Gardasil 9 |
| Pfizer INC. | $127.81 | 2019-2024 | |
| Sanofi Pasteur INC. | $118.66 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $67.02 | 2019-2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $61.45 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $51.53 | 2022-2025 | Doc Band |
| Seqirus USA INC | $51.33 | 2022-2023 | Flucelvax Quadrivalent |
| Neuronetics, INC. | $25.36 | 2025 | Neurostar Tms Therapy System |
| Kaleo, INC. | $22.76 | 2019-2021 | |
| Ucb, INC. | $22.03 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preeti Thabolingam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.